Pharma & biotech

Novo Nordisk partners with Swiss biotech firm on obesity – zebrafish to unlock new drugs

Novo Nordisk is teaming up with Swiss start-up Eracal Therapeutics, which is specialized in discovering new drugs from a zebrafish larvae platform. The firms will develop treatments targeted at food intake and other factors associated with obesity.
Zebrafish have been a hot topic withing drug discovery since the early 2000s, but it isn't until recently that the method has matured | Photo: Peter Hove Olesen/Politiken/Ritzau Scanpix
Zebrafish have been a hot topic withing drug discovery since the early 2000s, but it isn't until recently that the method has matured | Photo: Peter Hove Olesen/Politiken/Ritzau Scanpix
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersem

A new research collaboration between Novo Nordisk and a start-up from Switzerland, Eracal Therapeutics, has seen the light of day, a company press release announces.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs